



## Institutional Biosafety Committee Minutes

**Date:** Wednesday, June 17, 2026

**Time:** 9:31 AM

**Location:** Zoom Meeting

### MEMBERS IN ATTENDANCE

Busch, Robert H  
Finkernagel, Scott W.  
Geri, Jacob  
Kaminsky, Stephen M.  
McGuinn, Catherine  
Repik, Gabrielle  
Wagner, John A.

### MEMBERS ABSENT

Carroll, Ann M.  
Lieggi, Christine  
Ndhlovu, Lishomwa (Lish)  
Otero, Miguel  
Schnappinger, Dirk

### STAFF

Gonzalez Russi, Sabrina  
Lejb, Katarzyna

### Meeting Minutes for Approval:

- May 20, 2026

*No issues were raised and the committee approve the minutes from May 20, 2026.*

### Safety Officer Report

### New Business

- Previous meeting outstanding item was revisited by Scott, confirming that Mpox samples are not being stored in F2312, Dr. Glesby's laboratory.

### Conflicts of Interest Disclosure:

No member of the IBC may participate in the review of any project in which the IBC member is an investigator, has a financial conflict of interest, or has any other interest which has an adverse impact on the IBC member's ability to exercise independent judgment. Under such circumstances, the IBC member shall not be present during IBC deliberations, except to provide information requested by the IBC. Each member of the IBC shall respect and preserve the confidentiality of information he/she receives as a member of the IBC, and shall use, discuss, and/or disclose such information only for purposes related to deliberations or other assigned business of the IBC.

- *No Conflicts of Interest reported.*

## Protocols on Agenda

The Institutional Biosafety Committee (IBC) and Biosafety staff perform pre-reviews on all protocol submissions, including consideration of: agent characteristics (e.g., virulence, pathogenicity, environmental stability, replication competence), the types of manipulations planned, the sources of nucleic sequences (species), the nature of the nucleic acid sequences (e.g., structural, enzyme, oncogene, toxin, gene regulator), the hosts and vectors to be used, whether an attempt will be made to obtain expression of a transgene, and if so, the function of the protein in the proposed system.

IBC review includes: (i) independent assessment and setting of the containment levels required by the NIH Guidelines for the proposed research; (ii) assessment of the facilities, procedures, practices, and training and expertise of personnel involved in recombinant or synthetic nucleic acid molecule research; (iii) for recombinant or synthetic nucleic acid molecule research involving human research participants assessment focused on biosafety issues (e.g., administration, shedding) (iv) set containment levels in concert with the WCM IACUC.

Prior to reviewing a registration at the IBC meeting, the Principal Investigators laboratory is inspected to confirm that facilities and biocontainment equipment (e.g., certified Class II biological safety cabinets) are available and appropriate. We also determine if all laboratory personnel are appropriately trained to adhere to institutional and federal regulations to ensure the safe and compliant conduct of research.

All protocol submissions are made available to IBC members before the meeting. During the meeting, reviewers' and members' questions are presented, discussed, and sufficiently addressed. Protocols are voted on and acted upon by the IBC, i.e., applications are either approved, rejected or returned to the applicant to request clarifying information. Protocols deemed to require changes are returned to the PI for revision before subsequent review by the IBC. Principal Investigators are then provided the results of the IBC review and official approval.

Following initial approval, IBC registration remains valid for a period of two years. During this two-year period, laboratory inspections and review of training records of lab staff are conducted annually in accordance with Weill Cornell policies.

## Laboratory Safety Registrations - Initials

**Record Number:** 26-0032

**PI Name:** Yun Michael Shim

**Submission Type:** Initial

**Notes:** The assigned IBC member reviewed the lab protocols. No issues were raised. The reviewer recommended approval of Klebsiella and Influenza Virus at ABSL-2/BSL-2.

**Decision:** Approved

### **Biological/Microbiological Microorganism Tracking Table:**

Biological/Microbiological Microorganism Tracking Table:

| Microorganism for Biological/Micro biological work | Other microorganism name | List strains/serotypes for constructs                                      | Ability to replicate in the cell   | In vivo or in vitro? | Manipulation types performed/planned | Assigned Biosafety Level(s) | Regulatory Rationale | Applicable NIH Guidelines |
|----------------------------------------------------|--------------------------|----------------------------------------------------------------------------|------------------------------------|----------------------|--------------------------------------|-----------------------------|----------------------|---------------------------|
| Klebsiella [Pneumoniae]                            |                          | Klebsiella pneumoniae subsp. pneumoniae (Schroeter Trevisan (ATC C #43816) | Replication Competent              | Both                 | Introduction into in vivo model      | ABSL-2 ~ BSL-2              | Not rDNA             |                           |
| Influenza Virus [Orthomyxoviridae Ty pes A, B, C]  |                          | A/PR/8/34 (H1N 1) (UVa collaborator)                                       | Attenuated ~ Replication Competent | Both                 | Introduction into in vivo model      | ABSL-2 ~ BSL-2              | Not rDNA             |                           |

## Laboratory Safety Registrations - Amendments

**Record Number:** 23-0020

**PI Name:** Taha Merghoub

**Submission Type:** Amendment

**Notes:** The assigned IBC member reviewed the lab protocols. The amendment includes an addition of work with sleeping beauty transposon. No issues were raised. The reviewer recommended approval of Sleeping Beauty Transposon System at ABSL-2/BSL-2 due to the use of human cells and tumor cells.

**Decision:** Approved

#### Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

| Microorganism for Recombinant work | Other microorganism name          | List strains/serotypes for constructs | Ability to replicate in the cell | Cell/cell type where microorganism/vector will be propagated/packaged | In vivo or in vitro? | Cell type where expressed | Gene/gene family to be inserted, deleted, upregulated or downregulated            | Original source(s) species of DNA/RNA | Biological activity/potential of gene modification                                               | Manipulation types performed/planned                                                                                                     | Assigned Biosafety Level(s) | Regulatory Rationale | Applicable NIH Guidelines           |
|------------------------------------|-----------------------------------|---------------------------------------|----------------------------------|-----------------------------------------------------------------------|----------------------|---------------------------|-----------------------------------------------------------------------------------|---------------------------------------|--------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|----------------------|-------------------------------------|
| *Other                             | Sleeping Beauty Transposon System | N/A                                   | Attenuated                       | Human T cells, model T cells, human tumor cell lines.                 | Both                 | In vivo                   | Chimeric Antigen Receptors, including armored CARs, GFP and Luciferase reporters. | Other/ Salmonoid fish                 | Antibiotic Resistance ~ Gene Expression Regulators ~ Marker/Reporter ~ Other/ Chimeric receptors | Direct inject into in vivo model ~ Express/Upregulate gene of interest ~ Transfect cell line ~ Transfect cells / introduce in vivo model | ABSL-2 ~ BSL-2              | NIH Applicable       | Section II I-D-1 ~ Section III -D-4 |

-----  
**Record Number:** 25-0057

**PI Name:** Samara Reck-Peterson

**Submission Type:** Amendment

**Notes:** The assigned IBC member reviewed the lab protocols. The amendment includes an addition of work with Adeno-associated virus. No issues were raised. The reviewer recommended approval of AAV at BSL-2.

**Decision:** Approved

#### Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

| Microorganism for Recombinant work | Other microorganism name | List strains/serotypes for constructs | Ability to replicate in the cell  | Cell/cell type where microorganism/vector will be propagated/packaged | In vivo or in vitro? | Cell type where expressed | Gene/gene family to be inserted, deleted, upregulated or downregulated                    | Original source(s) species of DNA/RNA | Biological activity/potential of gene modification                                   | Manipulation types performed/planned  | Assigned Biosafety Level(s) | Regulatory Rationale | Applicable NIH Guidelines          |
|------------------------------------|--------------------------|---------------------------------------|-----------------------------------|-----------------------------------------------------------------------|----------------------|---------------------------|-------------------------------------------------------------------------------------------|---------------------------------------|--------------------------------------------------------------------------------------|---------------------------------------|-----------------------------|----------------------|------------------------------------|
| Adeno-Associated Virus (AAV)       |                          | AAV6.2 FF (ssAAV.TRE)                 | Replication Incompetent/Deficient | HEK293                                                                | In Vitro             | Human                     | LRRK2, Rab8, Rab10, Rab12, Ankyrin Repeats, Designed Proteins (DARPs) designed in our lab | Human                                 | Other/Signal transduction and membrane trafficking (basic cell biological processes) | Transfect cell line ~ Transfect cells | BSL-2                       | NIH Applicable       | Section II I-D-1 ~ Section III-D-3 |

## Laboratory Safety Registrations - 2-Year Renewals

-----  
**Record Number:** 19-0713

**PI Name:** Ching-Hwa Sung

**Submission Type:** Renewal

**Notes:** The assigned IBC member reviewed the lab protocols and noted changes, in vivo work and the additional gene expressed in lentivirus. No issues were raised. The reviewer recommended approval at previously approved biosafety levels.

**Decision:** Approved

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

| Microorganism for Recombinant work     | Other microorganism name | List strains/serotypes for constructs | Ability to replicate in the cell                        | Cell/cell type where microorganism/vector will be propagated/packaged | In vivo or in vitro? | Cell type where expressed | Gene/gene family to be inserted, deleted, upregulated or downregulated | Original source(s) species of DNA/RNA | Biological activity/potential of gene modification       | Manipulation types performed/planned                                                   | Assigned Biosafety Level(s) | Regulatory Rationale | Applicable NIH Guidelines          |
|----------------------------------------|--------------------------|---------------------------------------|---------------------------------------------------------|-----------------------------------------------------------------------|----------------------|---------------------------|------------------------------------------------------------------------|---------------------------------------|----------------------------------------------------------|----------------------------------------------------------------------------------------|-----------------------------|----------------------|------------------------------------|
| Lentivirus [Retroviridae/Lentiviridae] |                          | pLKO, pLenti-5                        | Replication Incompetent/Deficient                       | 293 cells                                                             | In Vitro             | In vivo ~ Human           | Tctex-1-shRNA, Clec4-shRNA, GFP, Clm1                                  | Human ~ Murine ~ Other                | Gene Expression ~ Regulators ~ Marker/Reporter ~ Unknown | Create virions ~ Express/Uregulate gene of interest ~ Transfect cell line              | BSL-2                       | NIH Applicable       | Section II I-D-1 ~ Section III-D-3 |
| Adeno-Associated Virus (AAV)           |                          | AAV-CMV vector, AAV-CR ALBP           | Replication Incompetent / Deficient ~ Self-Inactivating | HEK                                                                   | Both                 | In vivo ~ Bacterial       | cone ops in, GFP                                                       | Human ~ Murine                        | Gene Expression ~ Regulators ~ Marker/Reporter ~ Unknown | Create virions ~ Direct inject into in vivo model ~ Express/Uregulate gene of interest | ABSL-1 ~ BSL-1              | NIH Applicable       | Section II I-D-4                   |

Record Number: 23-0089

PI Name: Lauretta Lacko

Submission Type: Renewal

Notes: The assigned IBC member reviewed the lab protocols and noted no changes associated with this renewal. No issues were raised. The reviewer recommended approval at the previously approved biosafety level.

Decision: Approved

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

| Microorganism for Recombinant work     | Other microorganism name | List strains/serotypes for constructs | Ability to replicate in the cell                      | Cell/cell type where microorganism/vector will be propagated/packaged | In vivo or in vitro? | Cell type where expressed | Gene/gene family to be inserted, deleted, upregulated or downregulated | Original source(s) species of DNA/RNA | Biological activity/potential of gene modification | Manipulation types performed/planned                                                         | Assigned Biosafety Level(s) | Regulatory Rationale | Applicable NIH Guidelines          |
|----------------------------------------|--------------------------|---------------------------------------|-------------------------------------------------------|-----------------------------------------------------------------------|----------------------|---------------------------|------------------------------------------------------------------------|---------------------------------------|----------------------------------------------------|----------------------------------------------------------------------------------------------|-----------------------------|----------------------|------------------------------------|
| Lentivirus [Retroviridae/Lentiviridae] |                          | pLentiCRISPRv2, pLKO,pCS              | Replication Incompetent/Deficient ~ Self-Inactivating | HEK293T                                                               | In Vitro             | Human                     | lineage specific for pancreatic and colon development                  | Human                                 | Gene Expression ~ Regulators ~ Marker/Reporter     | Express/Uregulate gene of interest ~ Repress/Downregulate gene of interest ~ Transfect cells | BSL-2                       | NIH Applicable       | Section II I-D-1 ~ Section III-D-3 |

Acknowledgement of Laboratory Safety Registrations: No IBC-Applicable Work Conducted

| Record Number | PI Name        | Laboratory Safety Registration Submission Type |
|---------------|----------------|------------------------------------------------|
| 19-0715       | Francis Barany | Lab Registration - Renewal                     |
| 19-0719       | Kira Minkis    | Lab Registration - Renewal                     |

Laboratory Safety Registrations: Exempt

| Record Number | PI Name              | Laboratory Safety Registration Submission Type |
|---------------|----------------------|------------------------------------------------|
| 19-0716       | Gianpiero D. Palermo | Lab Registration - Renewal                     |

## Human Subjects Research/Human Gene Transfer: Annual Report

**HS Record Number:** 23-11026760

**HS PI Name:** Garrett, Kelly A

**Record Title:**

An Open-Label, Single-Center, Investigator Initiated Phase 1B Trial of E-CEL UVEC Cell Therapy for the Treatment of Chronic Anal Fissure

**RS Record Number:** 23-0151

**Notes:**

**Decision:** Approved

-----

**The meeting adjourned at 9:42 AM.**





